Physician profile
Zachary Trisel
NPI 1831540301
$9,165.60
in general payments reported to CMS, 2019-2025
62 companies · $1,604 in 2025
The $1,604 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $411 · 2022: $1,943 · 2023: $2,479 · 2024: $2,728 · 2025: $1,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,553 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,553.32 |
| Education | $258.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $864.51 | 2022-2025 | Kisqali, Piqray |
| Celgene Corporation | $710.33 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Regeneron Healthcare Solutions, INC. | $651.34 | 2022-2025 | Libtayo |
| Janssen Biotech, INC. | $564.69 | 2022-2025 | Erleada, Akeega, Balversa |
| Incyte Corporation | $521.87 | 2021-2025 | Monjuvi, Pemazyre, Jakafi |
| Daiichi Sankyo INC. | $476.33 | 2022-2025 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $462.15 | 2021-2025 | Calquence, Imfinzi, Enhertu |
| Pfizer INC. | $337.68 | 2022-2025 | |
| Eisai INC. | $305.05 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $258.53 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $241.68 | 2022-2025 | Polivy, Lunsumio, Columvi |
| Amgen INC. | $227.92 | 2021-2022 | |
| Genzyme Corporation | $224.20 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $210.35 | 2022-2024 | Iclusig, Ninlaro, Fruzaqla |
| Gilead Sciences, INC. | $208.60 | 2023-2025 | Trodelvy |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $198.06 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Epizyme, INC. | $196.67 | 2021 | |
| Beigene USA, INC. | $182.16 | 2022-2025 | Brukinsa, Tevimbra |
| Blueprint Medicines Corporation | $141.02 | 2021-2023 | Ayvakit |
| Exelixis INC. | $125.70 | 2023-2024 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $117.59 | 2022-2025 | Opdivo |
| Deciphera Pharmaceuticals INC. | $112.49 | 2022-2024 | Qinlock, Tgct |
| Astellas Pharma US INC | $112.34 | 2023-2025 | Xospata, Padcev, Vyloy |
| Tempus Ai, INC | $107.81 | 2024-2025 | Xt Cdx |
| Stemline Therapeutics INC. | $101.34 | 2023-2025 | Orserdu |
| Seagen INC. | $100.10 | 2021-2023 | Padcev, Tukysa, Tivdak |
| Sanofi-Aventis U.S. LLC | $98.00 | 2023 | |
| Glaxosmithkline, LLC. | $85.34 | 2023-2024 | Zejula, Jemperli, Ojjaara |
| Ipsen Biopharmaceuticals, INC | $83.55 | 2024-2025 | Onivyde, Somatuline Depot |
| Tersera Therapeutics LLC | $73.64 | 2024-2025 | Quzyttir, Zoladex |
| Adaptive Biotechnologies Corporation | $64.62 | 2023-2025 | Clonoseq |
| Karyopharm Therapeutics INC. | $64.05 | 2022-2023 | Xpovio |
| Pharmacosmos Therapeutics INC. | $63.65 | 2023-2025 | Monoferric |
| Adc Therapeutics America, INC. | $60.14 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.38 | 2023-2025 | |
| Sobi, INC | $57.44 | 2024-2025 | |
| Emd Serono, INC. | $55.96 | 2022-2025 | |
| Pharmaessentia USA Corporation | $55.63 | 2023-2024 | Besremi |
| Abbvie INC. | $49.61 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $46.63 | 2023 | Imbruvica |
| Apellis Pharmaceuticals, INC. | $41.82 | 2023-2024 | Empaveli |
| Servier Pharmaceuticals LLC | $41.56 | 2022-2024 | |
| Aveo Pharmaceuticals, INC. | $35.66 | 2023-2025 | Fotivda |
| Taiho Oncology, INC. | $34.87 | 2023-2024 | |
| Array Biopharma INC | $32.22 | 2022-2025 | Lorbrena, Mektovi, Braftovi |
| Beone Medicines USA, INC. | $29.26 | 2025 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.22 | 2024 | |
| Sun Pharmaceutical Industries INC. | $24.27 | 2023 | Odomzo, Yonsa |
| Progenics Pharmaceuticals, INC. | $21.39 | 2025 | |
| Dendreon Pharmaceuticals LLC | $19.80 | 2022 | |
| G1 Therapeutics, INC. | $18.78 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.26 | 2023 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $16.81 | 2022 | |
| Syndax Pharmaceuticals, INC. | $16.11 | 2025 | |
| Morphosys, US INC. | $15.42 | 2023 | Monjuvi |
| Genmab U.S., INC. | $15.28 | 2024 | Epkinly |
| Puma Biotechnology, INC. | $14.87 | 2024 | |
| Myriad Genetic Laboratories, INC. | $14.42 | 2025 | Myrisk |
| Agios Pharmaceuticals, INC. | $14.30 | 2025 | Pyrukynd |
| Sumitomo Pharma America, INC. | $13.09 | 2024 | Orgovyx |
| Veracyte, INC. | $12.24 | 2023 | |
| Coherus Oncology, INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Trisel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.